JP Morgan Chase
NVCT icon

JP Morgan Chase’s Nuvectis Pharma NVCT Stock Holding History

JP Morgan Chase’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Buy
7,091
+619
+10% +$6.93K ﹤0.01% 5609
2026
Q1 		$48.5K Buy
6,472
+90
+1% +$771 ﹤0.01% 6214
2025
Q4 		$48.2K Buy
6,382
+1,065
+20% +$6.94K ﹤0.01% 6244
2025
Q3 		$32K Sell
5,317
-946
-15% -$6.5K ﹤0.01% 6369
2025
Q2 		$46.8K Buy
6,263
+6,084
+3,399% +$55.2K ﹤0.01% 5951
2025
Q1 		$1.75K Hold
179
– – ﹤0.01% 6565
2024
Q4 		$968 Sell
179
-13
-7% -$81 ﹤0.01% 6740
2024
Q3 		$1.21K Sell
192
-14,561
-99% -$95.8K ﹤0.01% 6698
2024
Q2 		$93.4K Buy
14,753
+9,588
+186% +$65.2K ﹤0.01% 5545
2024
Q1 		$42.4K Buy
5,165
+263
+5% +$2.24K ﹤0.01% 6002
2023
Q4 		$40.9K Hold
4,902
– – ﹤0.01% 6057
2023
Q3 		$63.2K Sell
4,902
-558
-10% -$8.08K ﹤0.01% 5719
2023
Q2 		$87.2K Buy
+5,460
New +$87.2K ﹤0.01% 5523

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

JP Morgan Chase's NVCT Position: Q2 2026 in Review

JP Morgan Chase increased its Nuvectis Pharma (NVCT) stake by 9.6% in Q2 2026, buying an estimated $6.93K and bringing the position to 7,091 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #5609.

JP Morgan Chase first reported a position in NVCT in Q2 2023 and has held it in 13 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • JP Morgan Chase held 7,091 shares of Nuvectis Pharma worth $202K as of Q2 2026.
  • JP Morgan Chase bought 619 Nuvectis Pharma shares in Q2 2026, an estimated $6.93K.
  • Nuvectis Pharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5609 holding.
  • JP Morgan Chase first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 13 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.